Reprogramming based gene therapy for inherited red blood cell disorders.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Artificial blood for therapeutic and laboratory usage: Where do we stand?Biomicrofluidics · 2024
   Review
2. Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing.Stem cell research & therapy · 2020
   Review
3. Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC.Experimental & molecular medicine · 2016
   Article
4. Eliminate mitochondrial diseases by gene editing in germ-line cells and embryos.Protein & cell · 2015
   Article
5. Pluripotent stem cells and gene therapy.Translational research : the journal of laboratory and clinical medicine · 2013
   Review
6. The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders.Pharmaceuticals (Basel, Switzerland) · 2013
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as